Hypoxia-inducible factor-1a (HIF1a) is a crucial regulator of the cellular response to hypoxia through its regulation of genes that control erythropoiesis, angiogenesis and anaerobic metabolism. We have previously shown that HIF1a stability is regulated by SUMOylation under the hypoxic condition. However, how HIF1a became SUMOylated during hypoxia is still unknown. In this study we identify PIASy as a specific E3 ligase for hypoxia-induced HIF1a SUMOylation. Hypoxia promotes translocation of HIF1a to the nucleus to facilitate its binding to PIASy, enabling the conjugation of HIF1a by SUMO1. We further show that PIASy negatively regulates hypoxia-induced HIF1a stability and transactivation. Knocking down PIASy increases the angiogenic activity of endothelial cells. Moreover, we show an inverse relationship between expression of PIASy and tumor angiogenesis in colon cancer. Thus, we define an important role of PIASy in hypoxia signaling through promoting HIF1a SUMOylation.
Introduction
Hypoxia-inducible factor-1a (HIF1a) mediates hypoxia response by binding to canonical DNA sequences (hypoxia-responsive elements or HREs) in the promoters or enhancers of target genes (Wang et al., 1995; Carmeliet et al., 1998; Schofield and Ratcliffe, 2004; Gruber and Simon, 2006; Pouyssegur et al., 2006) . During normoxia, HIF1a is hydroxylated at two critical proline residues within oxygen-dependent degradation domain (ODD) by a family of oxygen-sensitive enzymes prolyl-4-hydroxylases, and degraded through ubiquitination and proteosome-dependent manner (Maxwell et al., 1999; Stebbins et al., 1999; Ohh et al., 2000; Bruick and McKnight, 2001; Ivan et al., 2001) . Because prolyl-4-hydroxylase is inactive under low concentration of oxygen, hypoxia limits HIF1a hydroxylation, allowing HIF1a to escape from normoxia-mediated degradation. HIF1a then translocates to nucleus to activate hypoxia-inducible genes (Jaakkola et al., 2001; Schofield and Ratcliffe, 2004) . Recently, several laboratories showed that hypoxia could induce HIF1a SUMOylation (Comerford et al., 2003; Bae et al., 2004; Shao et al., 2004; Berta et al., 2007; Carbia-Nagashima et al., 2007; Cheng et al., 2007) . These studies suggest that SUMOylation is important in the regulation of HIF1a under hypoxia condition, although the impact of SUMOylation on HIF1a activity is controversial (Bae et al., 2004; Berta et al., 2007; Carbia-Nagashima et al., 2007; Cheng et al., 2007) .
SUMOylation is catalyzed by the activating (E1), conjugating (E2) and ligating (E3) enzymes (Hay, 2005; Geiss-Friedlander and Melchior, 2007; Yeh, 2009 ). There are one E1, one E2 and more than eight SUMO E3 ligases reported in mammalian cells (Hay, 2005; Geiss-Friedlander and Melchior, 2007; Yeh, 2009) . During SUMOylation reactions, E3 ligase catalyzes the transfer of SUMO from E2 UBC9 to a substrate (Hay, 2005; Geiss-Friedlander and Melchior, 2007; Yeh, 2009) . It is well recognized that E3 ligase is an important regulator for protein SUMOylation (Hay, 2005; GeissFriedlander and Melchior, 2007; Yeh, 2009) . The largest group of SUMO E3 ligase is characterized by an SPRing motif (Hochstrasser, 2001; Jackson, 2001; Takahashi et al., 2001) , which can be subdivided into different families, including protein inhibitor of activated STAT (PIAS) family of proteins; MMS21, which is part of an octameric SMC5-SMC6 complex and Zip3, which is the meiosis-specific yeast protein (Hari et al., 2001; Johnson and Gupta, 2001; Kahyo et al., 2001; Sachdev et al., 2001; Takahashi et al., 2001; Branzei et al., 2006) . Other families of E3 ligases are described as without SP-Ring motif in its structure and include RanBP2 and Pc2. RanBP2 has been shown to be essential for topoisomerase IIa SUMOylation and chromosome segregation in cell mitosis (Dawlaty et al., 2008) . Pc2 is a component of polycomb protein complexes and can enhance SUMOylation of CtBP, HDAC4, MEF2 and LXRb (Kagey et al., 2003) .
PIAS proteins were first identified as negative regulators of STAT signaling (Shuai and Liu, 2005) . The mammalian PIAS family consists of five PIAS proteins, PIAS1, PIAS3, PIASxa, PIASxb and PIASy, which have significant sequence identity (more than 40%) and several functional domains and motifs that are conserved among the members (Shuai and Liu, 2005) . The Ring-finger domain located in the middle of PIAS is required for E3 ligase activity of PIAS proteins Schmidt and Muller, 2002) . PIASmediated SUMOylation of target proteins has been shown to involve in a wide range of cellular processes, including transcriptional control and protein-protein interactions Sachdev et al., 2001; Sapetschnig et al., 2002; Schmidt and Muller, 2002; Rogers et al., 2003; Mabb et al., 2006; Carter et al., 2007) .
In the previous study, we found that SUMOylated HIF1a could bind to VHL and be degraded even under hypoxia condition (Cheng et al., 2007) . SENP1 removes SUMO from SUMOylated HIF1a to stabilize HIF1a, allowing for HIF1a to participate in the regulation of hypoxia signaling (Cheng et al., 2007) . Although, along with other, we have reported that hypoxia could induce HIF1a SUMOylation (Comerford et al., 2003; Bae et al., 2004; Berta et al., 2007; Carbia-Nagashima et al., 2007) , it is unknown how HIF1a SUMOylation occurs in hypoxic condition. In this study, we identify PIASy as a specific E3 ligase for hypoxia-induced HIF1a SUMOylation. We find that hypoxia promotes interaction of PIASy with HIF1a, which is essential for HIF1a conjugation by SUMO1. Furthermore, PIASy is shown to regulate negatively hypoxia-HIF1a signaling through the induction of HIF1a SUMOylation.
Results

PIASy is the E3 ligase for hypoxia-induced HIF1a SUMOylation
We and others showed that hypoxia could induce global SUMO conjugation (Supplementary Figure S1 ) and HIF1a SUMOylation (Bae et al., 2004; Shao et al., 2004; Carbia-Nagashima et al., 2007; Cheng et al., 2007) . Because E3 ligase could promote SUMO conjugation, we reasoned that an E3 ligase might be involved in hypoxia-induced HIF1a SUMOylation. To identify the E3 ligase essential for HIF1a SUMOylation, we used an siRNA approach against known SUMO E3 ligases. To evaluate the efficiency and specificity of siRNAs, we isolated total RNA from 293 cells transfected with different E3 ligase siRNA and reverse transcription (RT)-PCR was performed to determine the expression level of endogenous SUMO E3 mRNAs. Figure 1a showed that siRNA could specifically knock down different SUMO E3 ligases. Thus, HIF1a SUMOylation was analyzed from the lysates of 293 cells transfected with siRNAs plus Flag-HIF1a and HA-SUMO1. PIASy siRNA is most efficient in abolishing hypoxia-induced HIF1a SUMOylation (Figure 1b) . The ability of PIASy in downregulating hypoxia-induced HIF1a SUMOylation was further shown by two additional PIASy siRNAs (Figure 1c ). We examined SUMOylation of endogenous HIF1a in PIASy siRNA-transfected 293 cells and found a similar result as in cells with cotransfection of HIF1a and SUMO1 (Figure 1d ). In addition, HIF1a conjugation by SUMO2, another member of SUMO family, was also significantly decreased in PIASy siRNA-transfected cells (Supplementary Figure S2 ).
To further determine whether this effect requires PIASy E3 ligase activity, we mutated the E3 catalytic domain of PIASy and compared its activity to SUMOylate HIF1a with that of wild-type PIASy. As shown in Figure 1e , overexpression of wild-type PIASy in 293 cells enhanced endogenous HIF1a SUMOylation. However, PIASy catalytic-inactivation mutant could not induce HIF1a SUMOylation under the same experimental condition. We further performed in vitro SUMOylation assay and found that addition of PIASy recombinant protein in the reaction mixture markedly increased the SUMOylation of HIF1a ODD, a fragment containing two SUMOylation sites (Figure 1f) .
Interestingly, we did not observe any changes in overall SUMO1 conjugation in PIASy siRNA-transfected cells (Supplementary Figure S3) , suggesting that PIASy specifically enhanced HIF1a SUMOylation. Because HIF2a was also reported as a SUMOylated protein (van Hagen et al., 2010) , we then examined whether PIASy was an E3 ligase for HIF2a SUMOylation. By using siRNA approach, we found that PIASxa, not other PIAS, was a specific E3 ligase for HIF2a SUMO conjugation (Supplementary Figure S4) . Taken together, PIASy is a specific E3 ligase for hypoxiainduced HIF1a SUMOylation.
Hypoxia induces the interaction of PIASy and HIF1a
During SUMO conjugation, E3 ligase binds to both target and UBC9 directly and then facilitates SUMO conjugation by catalyzing the transfer of SUMO from UBC9 to a substrate (Gong et al., 1997; Saitoh et al., 1998; Schwarz et al., 1998; Hay, 2005; Geiss-Friedlander and Melchior, 2007) . We first examined the binding of PIASy to HIF1a. 293 cells were transfected with FlagHIF1a and HA-PIASy. Flag-HIF1a was precipitated by anti-Flag antibody. As expected, HA-PIASy was present in HIF1a precipitates (Figure 2a ). This interaction was specific because other members of PIAS family could not co-precipitate with HIF1a.
It is well known that HIF1a translocates into nucleus under hypoxia condition (Kallio et al., 1998) . This process can be abolished by the mutation of the nuclear location signal (NLS) of HIF1a (Kallio et al., 1998) . Interestingly, NLS-mutated HIF1a could not be SUMOylated under hypoxia condition (Figure 2b ), indicating that hypoxia-induced nuclear translocation might be a prerequisite for HIF1a SUMOylation. Moreover, stabilization of HIF1a by hydroxylase inhibitor DMOG in normoxia did not increase HIF1a SUMOylation (Supplementary Figure S5 ), suggesting that increasing HIF1a stability by hypoxia is not enough for SUMO conjugation and the nuclear translocation of HIF1a is still need to initiate this process. Thus, hypoxia-driven nuclear translocation of HIF1a is proposed to be required for its interaction with PIASy, which is located in nucleus (Matsuura et al., 2005) . Indeed, PIASy coprecipitated with wild-type but not the NLS mutant (K719T) of HIF1a (Figure 2c ). To further confirm the interaction of PIASy and HIF1a occurred in nucleus, we extracted cytosolic and nuclear fractions from the 293 cells following transfection of Flag-HIF1a. Analysis of immunoprecipitates revealed a complex containing endogenous PIASy and Flag-HIF1a in nucleus, but not in cytosol (Figure 2d) .
The above results suggest that HIF1a nuclear translocation is critical for its interaction with PIASy.
Because hypoxia can promote HIF1a nuclear localization, we hypothesized that it might facilitate binding of HIF1a to PIASy. To address this issue, we used a binding assay based on Gal4 interaction reporter analysis system to monitor in vivo interaction of PIASy and HIF1a in cells under hypoxia condition. We generated plasmids of HIF1a fused with active domain (AD) and PIASy fused with binding domain (BD). These plasmids along with Gal4-luciferase were transfected into 293 cells. The luciferase activity was measured in these transfected cells with or without hypoxia treatment. As shown in Figure 2e , luciferase activity was significantly increased following the hypoxia treatment, indicating that hypoxia can induce the interaction between HIF1a and PIASy in vivo.
Interaction of PIASy and HIF1a is essential for hypoxia-induced HIF1a SUMOylation
To determine the domains responsible for the interaction between HIF1a and PIASy, we generated a series P IA S x α /x β P IA S 3 P IA S y R a n B P 2 P c 2 M M S 2 1 M o c k P IA S 1 P IA S x α /x β P IA S 3 P IA S y R a n B P 2 P c 2 The mixture of GST-ODDpm, SUMO1 and E1 was incubated for 1 h at 37 1C with UBC9 and GST-PIASy as indicated. The GST-ODDpm was pull-downed from reaction mixture by GST beads and analyzed by western blot with anti-HIF1a antibody.
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X Kang et al of truncated mutants of PIASy or HIF1a. In the experiments to identify the PIASy binding region on HIF1a, we determined that both regions of 211-330 and 331-698 amino acid of HIF1a could individually interact with PIASy ( Figure 3a) . Interestingly, region 331-698 amino acid is the ODD domain of HIF1a containing SUMO conjugation sites (Ohh et al., 2000; Ivan et al., 2001; Jaakkola et al., 2001) . ODD domain has been shown to be a SUMO conjugation target for PIASy E3 ligase activity in in vitro assay (Figure 1e ). Thus we thought that binding of PIASy to ODD domain (331-698) was sufficient for HIF1a SUMOylation under hypoxia condition. However, the role of the association between region of 211-330 of HIF1a and PIASy is unknown. Using similar strategy, we mapped the BD of HIF1a to the N-terminal region, most likely between 150 and 202 amino acid of PIASy (Figure 3b ). Because this fragment can bind to HIF1a, it could serve as a dominant-negative inhibitor for PIASy E3 ligase activity through competitively binding with HIF1a. Indeed, expression of PIASy (150-202) fragment could decrease the binding of full-length PIASy to HIF1a (Figure 3c ). The competitive binding was also confirmed in in vivo Gal4 interaction reporter assay, which showed that the luciferase activity induced by the interaction of PIASy Difference between normoxia and hypoxia was significant (Po0.01, t-test).
PIASy regulates HIF1a SUMOylation X Kang et al and HIF1a was decreased by expression of PIASy (150-202) fragment (Figure 3d ). More importantly, overexpression of PIASy (150-202) decreased HIF1a SUMOylation promoted by PIASy (Figure 3e ), indicating that the disruption of the interaction could abrogate the E3 ligase activity of PIASy for HIF1a SUMOylation. These results also suggest that the binding of PIASy to HIF1a is crucial for hypoxia-induced HIF1a SUMOylation.
PIASy negatively regulates HIF1a stability and activity
We and others reported a controversial consequence of SUMOylation on HIF1a activity (Bae et al., 2004; Berta et al., 2007; Carbia-Nagashima et al., 2007; Cheng et al., 2007) . Bae et al. (2004) showed that SUMO-1 increased HIF1a protein level and its activity in SUMO1-overexpressed cells. Carbia-Nagashima et al. (2007) reported that RSUME could enhance HIF1a SUMOylation and its activity through its interaction with UBC9. However, Berta et al. (2007) reported that HIF-dependent transcriptional activity is increased in SUMO-deficient HIF1a by co-transfection of siRNA targeted to endogenous HIF1a together with HIF1a siRNA-resistant expression vectors carrying mutations for SUMO modification. In our previous study, we used SENP1
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X Kang et al regulation of HIF1a stability through de-SUMOylation of HIF1a (Cheng et al., 2007) . To show directly the relationship between HIF1a SUMOylation and its activity, we performed an HRE reporter gene assay in SENP1 À/À MEF cells and showed that the mutation of HIF1a SUMOylation sites could increase its transcriptional activity in response to hypoxia (Figure 4a) Figure S6 ). Importantly, HIF1a protein level significantly increased in PIASy-silenced SENP1 À/À MEF cells, especially under hypoxia condition (Figure 4b ), indicating that endogenous PIASy could decrease HIF1a stability. To determine the functional consequence of action of PIASy on HIF1a stabilization, we analyzed the expression of vascular endothelial growth factor (VEGF) and Glut-1, which are HIF1a target genes, in PIASy-silenced SENP1 À/À MEF cells. As shown in Figure 4c , hypoxia-induced expression of both target genes markedly increased in PIASy-silenced SENP1 À/À MEF cells in comparison to that of scramble siRNA cells. We further confirmed the effect of PIASy on HIF1a activity by performing an HIF1a-dependent luciferase assay in SENP1 À/À MEF cells. Overexpression of PIASy significantly decreased hypoxia-induced HIF1a transactivation (PIASy WT vs control, Figure 4d ). However, mutation of PIASy E3 ligase activity (PIASy Mut) abrogated the effect of PIASy on HIF1a transactivation (Figure 4d) . Similarly, PIASy (150-202), a fragment that can specifically disrupt the PIASy interaction with HIF1a, markedly increased hypoxia-induced HRE-luciferase in dose-dependent manner (Figure 4e ). These results suggest PIASy exerted a negative effect on HIF1a stability and activity.
PIASy negatively regulates angiogenesis
Above results suggest that PIASy might regulate HIF1a biological function through HIF1a SUMOylation. Figure S7) . Real-time PCR assay confirmed the increase of VEGF mRNA expression in the PIASy siRNA cells (Figure 5a) . Importantly, PIASy silencing increased the tube formation of HUVEC cells during hypoxia treatment (Figure 5b ), indicating that PIASy negatively regulates angiogenic activity of endothelial cells.
To further investigate the significance of PIASy action on angiogenesis, we determined the association between PIASy and angiogenesis in colon cancer samples by immunohistochemistry. A series of sections from 32 colon cancer samples and 4 normal colon tissue samples were immunostained with anti-PIASy (aPIASy) and CD31 (aCD31) antibodies. As PIASy-positive cells were detected to distribute mainly in the stroma of normal and colon cancer tissues (Figure 5c) , we focused the analysis on the cells in stroma. Immunohistochemical scoring was determined by the intensity of the distribution of positive cells (for PIASy staining) or angiogenesis (CD31 staining) in the stroma. We set the average score of normal tissues as baseline. The tumor tissues with scores more than 50% the baseline were designated as PIASy or angiogenesis high, and others were designated as PIASy or angiogenesis low. We found a significantly negative correlation between PIASy expression and intensity of angiogenesis (Table 1) . Among 17 cases with PIASy high, 10 cases were with angiogenesis low (Table 1 ; case 1 in Figure 5c ). However, the 12 of 15 cases with PIASy low showed high density of blood vessels indicated by anti-CD31 staining within the stroma of these samples (Table 1 ; case 2 in Figure 5c ). These results suggest that PIASy is a negative regulator for tumor angiogenesis in colon cancer.
Discussion
HIF1a is pivotal in the regulation of gene transcription in response to hypoxia. The stability and subsequent transactivational function of HIF1a has been shown to be regulated by posttranslational modification (Brahimi-Horn et al., 2005) . Hydroxylation of HIF1a on two proline residues by prolyl-4-hydroxylase is the signal for interaction with the E3 ubiquitin ligase VHL, and subsequent polyubiquitination and degradation of HIF1a under normoxia (Ivan et al., 2001; Jaakkola et al., 2001) . Hydroxylation of N803 in the C terminus of HIF1a by FIH leads to inactivation of its transcriptional activity by precluding the binding of p300/CBP (Lando et al., 2002) . Phosphorylation and acetylation of HIF1a have also been reported as regulation mechanisms for its activation (Brahimi-Horn et al., 2005) .
We and others have shown that HIF1a is modified by SUMO under hypoxia condition. Carbia-Nagashima et al. (2007) have reported that RSUME can enhance global SUMO conjugation by interacting with UBC9. They further found that the expression of RSUME is induced by hypoxia, and consequently HIF1a SUMOylation increased. In this study, we identify a specific E3 ligase for HIF1a SUMOylation, which is promoted by hypoxia (Figure 5d ). The conclusion is made based on the following evidences. First, PIASy siRNA, not other E3 siRNAs, decreases SUMO1 modification of HIF1a and increases the activity of HIF1a in response to hypoxia. Second, overexpression of PIASy promotes the HIF1a SUMOylation even in the cells without hypoxia treatment. In contrast, a catalytic mutant of PIASy blocks HIF1a SUMOylation. Third, recombinant PIASy protein significantly increases HIF1a SUMO conjugation in vitro. Fourth, hypoxia induces the binding of PIASy to HIF1a. Bae et al. (2004) previously reported that SUMO-1 increased HIF1a protein level and its activity in SUMO1-overexpressed cells. Carbia-Nagashima et al. (2007) reported that RSUME could enhance HIF1a SUMOylation and its activity. These studies were carried out in the presence of SENP1. In contrast, our previous report (Cheng et al., 2007) and the current studies have used SENP1 1 À/À MEF cells to show the importance of SENP1 in the regulation of HIF1a stability and activity through de-SUMOylation of HIF1a. In support of our results, Berta et al. (2007) reported that HIF-dependent transcriptional activity is increased in SUMO-deficient HIF1a by co-transfection of siRNA targeted to endogenous HIF1a together with HIF1a siRNA-resistant expression vectors carrying mutations for SUMO modification. Another possibility for the difference observed by Bae et al. (2004) and Carbia-Nagashima et al. (2007) may be due to an indirect effect on HIF1a through SUMOylation of other proteins caused by overexpression of SUMO1 or RSUME in their system.
Our study shows that hypoxia-driven HIF1a nuclear translocation is a crucial process for HIF1a SUMOylation promoted by PIASy. It has been shown that HIF1a nuclear accumulation is dependent on an NLS within the C-terminal end of HIF1a (Kallio et al., 1998) . A single amino-acid substitution within the NLS sequence motif (K719T) can inhibit HIF1a nuclear translocation (Kallio et al., 1998) and results in inhibition of HIF1a SUMOylation (Figure 2b) . Moreover, the interaction between HIF1a and PIASy occurs mainly in nucleus, which is essential for PIASy-mediated HIF1a SUMOylation. Thus, these results suggest that the HIF1a nuclear accumulation is a prerequisite for hypoxia-induced HIF1a SUMOylation.
We mapped a PIASy BD on HIF1a locating in residues 331-698 of HIF1a. This domain is in the ODD, which contains two prolyl residues (P402 and 564) for The 32 surgical specimens of colon cancer were stained with antiPIASy and anti-CD31 antibodies as shown in Figure 5c . Expression patterns in all samples are summarized here. The Pearson's w 2 -test was used to analyze the significance of the relationship between PIASy expression and intensity of angiogenesis expression (Po0.025).
PIASy regulates HIF1a SUMOylation X Kang et al hydroxylation that lead to degradation under normoxia (Ivan et al., 2001; Jaakkola et al., 2001) . ODD domain also contains two SUMOylation sites (K391 and 477), and SUMOylation can cause HIF1a degradation under hypoxia (Cheng et al., 2007) . We showed this domain is SUMOylated in PIASy-dependent manner (Figure 1f ).
In conclusion, in this study we found that PIASy is an E3 ligase, which negatively regulates HIF1a stability and transactivation, and downregulates VEGFmediated angiogenesis. Thus, we defined an important role of PIASy in hypoxia-HIF1a signaling. These results may provide a molecular basis to use PIASy as a new target for antiangiogenic therapies.
Materials and methods
Antibodies, plasmids, siRNA and cell lines Antibodies against HIF1a (catalog no. NB-105) were purchased from Novus (Littleton, CO, USA). PIASy (catalog no. sc-50347) and Myc (catalog no. sc-40) antibodies were purchased from Santa Cruz Corp. (Santa Cruz, CA, USA). Anti-Flag antibody (M2, catalog no. F3165) was from Sigma (St Louis, MO, USA). Anti-HA antibody (16B12, catalog no. MMS-101P) was purchased from Covance (Princeton, NJ, USA). Anti-SUMO1 antibody (catalog no. 18-2306) was purchased from Zymed (Mason, OH, USA).
Plasmid pcDNA3-Flag-PIASy truncates (1-100, 1-202, 1-323, del RF, 324-511, 1-511) were provided by Guangchao Sui (Wake Forest University, USA); HA-PIAS1, HA-PIASxa, HA-PIASxb, HA-PIAS3, HA-PIASy and GST-PIASy were provided by Xinhua Feng (Baylor College of Medicine, USA); pcDNA3-myc PIASy wt, pCMV-Flag-PIASy WT and pCMVFlag-PIASy Mut, a PIASy catalytic mutant, were provided by Shigeki Miyamoto (University of Wisconsin-Madison, USA). Myc-HIF2a was provided by Longsheng Lu (Texas Heart Institute, USA). HA-SUMO-1, GST-ODDpm and HRE-luc were previously described. Flag-HIF1a, Flag-HIF1a Mut, HA-HIF1a, Flag-HIF1aK719T, Flag-HIF1a truncates were generated using standard cloning procedures and PCR-based mutagenesis. AD-HIF1a and BD-PIASy were generated based on Mammalian Matchmaker two-hybrid system purchased from Clontech (Mountain View, CA, USA).
siRNA against PIAS1 (catalog no. M-008167-01), PIASxa/ xb (catalog no. J-006033-05), PIAS3 (catalog no. J-006034-05), PIASy (catalog no. J-005946-05), RanBp2 (catalog no. J-006044-05), Pc2 (catalog no. J-006035-05), MMS21 (catalog no. L-018070-00) and nonspecific siRNA (catalog no. D-001810-01) were purchased from Dharmacon RNA Technologies (Lafayette, CO, USA). PIASy-Si1 (against human PIASy1: 5 0 -GTGCTCTACGGAAAGTACTT-3 0 ), PIASy-Si2 (against human PIASy: 5 0 -CAAGACAGGTGGAGTTGAT-3 0 ) and mPIASy-Si (against mouse PIASy: 5 0 -GTGCTGTACGG GAAGTACTT-3 0 ) were generated based on Knockout RNAiReady pSIREN-RetroQ Vector system purchased from Clontech.
HUVEC cell was purchased from ATCC. 293 cell was purchased from Invitrogen (Carlsbad, CA, USA). SENP1 MEF cells were previously described (Cheng et al., 2007) .
Human colon cancer tissue specimens
All the formalin-fixed and paraffin-embedded colon cancer tissue specimens were obtained from the colon cancer tissue banks maintained by the Cancer Hospital of Chinese Academy of Medical Science and Peking Union Medical College. The tissue specimens had been obtained during colectomy in 32 colon cancer patients. The histopathology of the specimens was determined by pathologists in the same hospital. Real-time quantitative PCR Total RNA was isolated by Trizol kit (Invitrogen). RNA was treated with DNase (Promega, Madison, WI, USA). Complementary DNA was synthesized using the cDNA synthesis kit (Takara, Shiga, Japan) according to the manufacturer's instructions. Fluorescence real-time RT-PCR was performed with the double-stranded DNA dye SYBRGreen PCR Core Reagents (PE Biosystems, Warrington, UK) using the ABI PRISM 7300 System (PerkinElmer, Torrance, CA, USA). PCR was carried out in triplicate and standard deviations representing experimental errors were calculated. All data were analyzed using ABI PRISM SDS 2.0 software (PerkinElmer). Pairs of PCR primers used to amplify the target genes were as follows: hVEGF (forward: 5 0 -TTTCTGCTGTCTTGGGTG CATTGG-3 0 , reverse: 5 0 -ACCACTTCGTGATGATTCTGC CCT-3 0 ), mVEGF (forward: 5 0 -TCACCAAAGCCAGCACA TAGGAGA-3 0 , reverse: 5 0 -TTTCTCCGCTCTGAACAAGG CTCA-3 0 ), mGlut-1 (forward: 5 0 -TCAACGAGCATCTTCG AGAAGGCA-3 0 , reverse: 5 0 -TCGTCCAGCTCGCTCTACA ACAAA-3 0 ), 18S (forward: 5 0 -AGGCCCTGTAATTGGAAT GAGTC-3 0 , reverse: 5 0 -GCTCCCAAGATCCAACTACGAG-3 0 ).
RT-PCR
Immunoprecipitation 293 cells (5 Â 10 6 ) pellets were lysed in 1 ml of radioimmune precipitation assay buffer (50 mM Tris-HCl (pH 7.4), 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS and 350 mM NaCl) containing 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, 10 mg/ml aprotinin, 1.5 mM pepstatin, 1 mM Na 3 VO 4 and 5 mM N-ethylmaleimide. For hypoxia treatment, the cells were be treated by addition of MG132 (10 mM) for 4 h before collection. Cell lysis was performed for 30 min on ice, and DNA in the sample was sheared with a 22-gauge needle. After centrifugation at 20 000 g for 10 min at 4 1C, the supernatants were added to appropriate antibody coupled to 20 ml of protein G-Sepharose beads (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The bead suspensions were rotated for 3 h at 4 1C. Beads were then washed five times with
